Kasabach-Merritt syndrome

Sheilagh Maguiness, Lyn Guenther

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

Background: Kasabach-Merritt syndrome (KMS) is a consumptive coagulopathy associated with the presence of a large vascular lesion. It is often a frustrating condition to treat and it carries a high mortality rate. There are currently no known treatment guidelines. Kasabach-Merritt syndrome is associated with kaposiform hemangioendothelioma (KHE) and tufted angioma (TA); these lesions, when associated with KMS, are locally invasive, aggressive vascular tumors. Treatment options include supportive care, local therapies, and drug and surgical management. In most recent case reports, a multimodal approach to therapy is taken. Objective and Conclusion: The objective of this article is to provide a comprehensive review of KMS and give an up-to-date summary of treatment options. The clinical presentation, laboratory findings, vascular pathology, and pathophysiology will also be discussed.

Original languageEnglish (US)
Pages (from-to)335-339
Number of pages5
JournalJournal of Cutaneous Medicine and Surgery
Volume6
Issue number4
DOIs
StatePublished - Jul 1 2002

Fingerprint

Kasabach-Merritt Syndrome
Blood Vessels
Medication Therapy Management
Guidelines
Pathology
Mortality
Neoplasms

Cite this

Kasabach-Merritt syndrome. / Maguiness, Sheilagh; Guenther, Lyn.

In: Journal of Cutaneous Medicine and Surgery, Vol. 6, No. 4, 01.07.2002, p. 335-339.

Research output: Contribution to journalReview article

Maguiness, Sheilagh ; Guenther, Lyn. / Kasabach-Merritt syndrome. In: Journal of Cutaneous Medicine and Surgery. 2002 ; Vol. 6, No. 4. pp. 335-339.
@article{d1f2b11734bc41c4a1a9b85892bbe9c6,
title = "Kasabach-Merritt syndrome",
abstract = "Background: Kasabach-Merritt syndrome (KMS) is a consumptive coagulopathy associated with the presence of a large vascular lesion. It is often a frustrating condition to treat and it carries a high mortality rate. There are currently no known treatment guidelines. Kasabach-Merritt syndrome is associated with kaposiform hemangioendothelioma (KHE) and tufted angioma (TA); these lesions, when associated with KMS, are locally invasive, aggressive vascular tumors. Treatment options include supportive care, local therapies, and drug and surgical management. In most recent case reports, a multimodal approach to therapy is taken. Objective and Conclusion: The objective of this article is to provide a comprehensive review of KMS and give an up-to-date summary of treatment options. The clinical presentation, laboratory findings, vascular pathology, and pathophysiology will also be discussed.",
author = "Sheilagh Maguiness and Lyn Guenther",
year = "2002",
month = "7",
day = "1",
doi = "10.1007/s10227-001-0055-4",
language = "English (US)",
volume = "6",
pages = "335--339",
journal = "Journal of Cutaneous Medicine and Surgery",
issn = "1203-4754",
publisher = "Decker Publishing",
number = "4",

}

TY - JOUR

T1 - Kasabach-Merritt syndrome

AU - Maguiness, Sheilagh

AU - Guenther, Lyn

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Background: Kasabach-Merritt syndrome (KMS) is a consumptive coagulopathy associated with the presence of a large vascular lesion. It is often a frustrating condition to treat and it carries a high mortality rate. There are currently no known treatment guidelines. Kasabach-Merritt syndrome is associated with kaposiform hemangioendothelioma (KHE) and tufted angioma (TA); these lesions, when associated with KMS, are locally invasive, aggressive vascular tumors. Treatment options include supportive care, local therapies, and drug and surgical management. In most recent case reports, a multimodal approach to therapy is taken. Objective and Conclusion: The objective of this article is to provide a comprehensive review of KMS and give an up-to-date summary of treatment options. The clinical presentation, laboratory findings, vascular pathology, and pathophysiology will also be discussed.

AB - Background: Kasabach-Merritt syndrome (KMS) is a consumptive coagulopathy associated with the presence of a large vascular lesion. It is often a frustrating condition to treat and it carries a high mortality rate. There are currently no known treatment guidelines. Kasabach-Merritt syndrome is associated with kaposiform hemangioendothelioma (KHE) and tufted angioma (TA); these lesions, when associated with KMS, are locally invasive, aggressive vascular tumors. Treatment options include supportive care, local therapies, and drug and surgical management. In most recent case reports, a multimodal approach to therapy is taken. Objective and Conclusion: The objective of this article is to provide a comprehensive review of KMS and give an up-to-date summary of treatment options. The clinical presentation, laboratory findings, vascular pathology, and pathophysiology will also be discussed.

UR - http://www.scopus.com/inward/record.url?scp=0036653119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036653119&partnerID=8YFLogxK

U2 - 10.1007/s10227-001-0055-4

DO - 10.1007/s10227-001-0055-4

M3 - Review article

VL - 6

SP - 335

EP - 339

JO - Journal of Cutaneous Medicine and Surgery

JF - Journal of Cutaneous Medicine and Surgery

SN - 1203-4754

IS - 4

ER -